Beyond BTK inhibitors, B-cell lymphoma-2 (Bcl-2) inhibitors and PI3K inhibitors, either as monotherapies or in combination, have emerged as promising therapeutic strategies for preventing CLL-RT [19,20]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.